Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT

Concurrent chemoradiotherapy (cCRT) is the standard treatment for patients with negative epidermal growth factor receptor (EGFR)-mutated unresectable locally advanced non-small cell lung cancer (LA-NSCLC). However, parts of patients only receive sequential chemoradiotherapy (sCRT) due to various reasons. This phase II study aimed to improve the outcomes of patients receiving sCRT by combining anti-angiogenesis therapy (Anlotinib) during radiotherapy course.We hypothesize that the combination of radiotherapy with anlotinib could improve the 2-year PFS rate from 35% with sCRT to 50. The accrual

Trial Details

NCT ID
NCT07037680
Phase
PHASE2
Sponsor
JIANYANG WANG
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Anlotinib
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • ≥18 years old with no restrictions on sex;
  • Peripheral tumor, or central lung cancer with non-squamous tissue or a mixed tissue with less than 50% squamous carcinoma;
  • Eastern cooperative oncology group (ECOG) score ≤2 was required;
  • Received systemic chemotherapy or combined chemotherapy and immumitherapy for ≥ 4 weeks without progression;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →